Sugi Predict

Sugi Predict / Compounds / SCHEMBL931252

SCHEMBL931252

SCHEMBL931252

CCCCCC(=O)NC1CCCCC1

nearest known ligand 0.96

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.78
▸ GNAI3 P08754 1/20 0.66
▸ GNAO1 P09471 1/20 0.66
▸ GNAI1 P63096 1/20 0.66
▸ HDAC3 O15379 2/20 0.66
▸ HDAC1 Q13547 2/20 0.66
▸ HDAC2 Q92769 2/20 0.66
▸ HDAC10 Q969S8 2/20 0.66
▸ HDAC11 Q96DB2 2/20 0.66
▸ HDAC8 Q9BY41 2/20 0.66
▸ HDAC6 Q9UBN7 2/20 0.66
▸ NCOR2 Q9Y618 1/20 0.66
▸ EPHX1 P07099 9/20 0.60
▸ ALDH1A1 P00352 2/20 0.59
▸ EPHX2 P34913 2/20 0.58
▸ HPGD P15428 2/20 0.58
▸ MEN1 O00255 1/20 0.58
▸ MAPT P10636 1/20 0.58
▸ KMT2A Q03164 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22055472 1.00 SMN1; SMN2 (0.78) SMN1; SMN2GNAI3GNAO1GNAI1HDAC3
SCHEMBL11080983 0.98 SMN1; SMN2 (0.75) SMN1; SMN2GNAI3GNAO1GNAI1HDAC3
SCHEMBL1456476 0.98 SMN1; SMN2 (0.75) SMN1; SMN2GNAI3GNAO1GNAI1HDAC3
SCHEMBL28519164 0.98 SMN1; SMN2 (0.75) SMN1; SMN2GNAI3GNAO1GNAI1HDAC3
SCHEMBL5002618 0.98 SMN1; SMN2 (0.75) SMN1; SMN2GNAI3GNAO1GNAI1HDAC3
Hexadecanoic Acid Cyclohexylamide SCHEMBL1456860 0.98 SMN1; SMN2 (0.75) SMN1; SMN2GNAI3GNAO1GNAI1HDAC3
SCHEMBL21443012 0.98 SMN1; SMN2 (0.75) SMN1; SMN2GNAI3GNAO1GNAI1HDAC3
SCHEMBL21442874 0.98 SMN1; SMN2 (0.75) SMN1; SMN2GNAI3GNAO1GNAI1HDAC3
SCHEMBL12196021 0.98 SMN1; SMN2 (0.75) SMN1; SMN2GNAI3GNAO1GNAI1HDAC3
SCHEMBL30590541 0.98 SMN1; SMN2 (0.75) SMN1; SMN2GNAI3GNAO1GNAI1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114031477-B Method for reducing amide compounds into amine compounds by cobalt catalysis 浙江工业大学 2023-12-05 — — CN disclosed
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 — — US disclosed
CN-113999131-B Method for preparing amide derivative by amination of alkyl C-H bond under catalysis of nickel promoted by visible light 苏州大学 2022-06-28 — — CN disclosed
CN-113999131-A Method for preparing amide derivative by amination of alkyl C-H bond under catalysis of nickel promoted by visible light 苏州大学 2022-02-01 — — CN disclosed
US-9884814-B2 Acylguanidines for treating osteoarthritis MERCK PATENT GMBH (DE) 2018-02-06 — — US disclosed
US-20150361037-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-12-17 — — US disclosed
CN-101605781-B Aryl carboxylic acid cyclohexyl amide derivatives NOVARTIS AG 2014-08-13 — — CN disclosed
CN-101605781-B Aryl carboxylic acid cyclohexyl amide derivatives NOVARTIS AG 2014-08-13 — — CN disclosed
US-8354431-B2 Aryl carboxylic acid cyclohexyl amide derivatives NOVARTIS AG (CH) 2013-01-15 — — US disclosed
WO-2011000945-A9 AMINOALKAMIDES FOR USE IN THE TREATMENT OF INFLAMMATORY, DEGENERATIVE OR DEMYELINATING DISEASES OF THE CNS NENSIUS RESEARCH A/S (DK) 2011-04-07 — — WO disclosed
US-20070027325-A1 Process for the preparation of cilostazol and of the intermediates thereof DIPHARMA S.P.A. (IT) 2007-02-01 — — US disclosed
US-5703129-A 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production BRISTOL-MYERS SQUIBB COMPANY (US) 1997-12-30 — — US disclosed
EP-0778266-A1 5-Amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of beta-amyloid protein production BRISTOL-MYERS SQUIBB COMPANY (US) 1997-06-11 — — EP disclosed
EP-0515420-B1 NITRIC ACID ESTERS OF CYCLOHEXANOL DERIVATIVES BOEHRINGER MANNHEIM GMBH (DE) 1996-06-12 — — EP disclosed
EP-0515420-A1 NITRIC ACID ESTERS OF CYCLOHEXANOL DERIVATIVES. BOEHRINGER MANNHEIM GMBH (DE) 1992-12-02 — — EP disclosed
WO-1991012230-A1 NITRIC ACID ESTERS OF CYCLOHEXANOL DERIVATIVES BOEHRINGER MANNHEIM GMBH (DE) 1991-08-22 — — WO disclosed
US-4134842-A Molded plastic bearing assembly KAMATICS CORPORATION (US) 1979-01-16 — — US disclosed
US-4053665-A MOLDED PLASTIC BEARING ASSEMBLY KAMATICS CORPORATION (US) 1977-10-11 — — US disclosed
US-4048370-A Shaped bearing member KAMATICS CORPORATION (US) 1977-09-13 — — US disclosed
US-3996143-A Cured acrylate bearing member KAMATICS CORPORATION (US) 1976-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT SMN1; SMN2 610/4885GNAI3 678/4885GNAO1 340/4885
US-20070027325-A1 Process for the preparation of cilostazol and of the intermediates thereof CILK1, WNK3, PDE3A SMN1; SMN2 1919/4885GNAI3 575/4885GNAO1 1572/4885
US-20150361037-A1 ACYLGUANIDINES FOR TREATING OSTEOARTHRITIS CTSG, CTSD, CTSB SMN1; SMN2 3634/4885GNAI3 1353/4885GNAO1 794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.